Photo of Genesis Sanchez Tavarez

Genesis Sanchez Tavarez is an associate in the Litigation Department. Her practice encompasses a broad range of high-profile complex litigation matters across the country, with a particular emphasis on product liability, antitrust and contract disputes. Genesis has experience representing clients at all stages of litigation. Her experience also spans a wide array of industries, such as pharmaceuticals, professional sports, and consumer products.

Genesis has previously undertaken three client secondments while at Proskauer. As a summer associate, she worked as a labor relations associate in the labor department of the Broadway League. In her first year, Genesis spent five months serving as Special Assistant Corporation Counsel in the Commercial and Real Estate Division of the New York City Law Department. More recently, as a second year, Genesis spent six months at Takeda Pharmaceuticals USA where she served as counsel in US Litigation & Investigations.

Genesis is also member of Proskauer’s Diverse Lawyers Network as well as Proskauer’s Hispanic Lawyers Affinity Group and Black Lawyers Affinity Group. In 2022, Genesis served as a member of the Summer Program Committee. Genesis was also a Proskauer Silver Scholar.

Prior to joining Proskauer, Genesis earned her J.D. From Columbia Law School, where she was a part of the Immigrants’ Rights Clinic and the Refugee and Asylum Moot Court, vice president of the Latinx Law Student Association, and a staffer on the Human Rights Law Review Journal’s Jailhouse Manual. Genesis was also a visiting scholar at King’s College London in their Master of Laws (LLM) program. Additionally, Genesis has a Bachelor of Arts in Political Science, Justice Studies, and Public Administration. 

With Hollywood celebrities speaking out both in favor of and against the use of drugs like Ozempic and Wegovy for weight loss, it was only a matter of time before demand outpaced supply. Although most might believe that increased demand is a good problem to have, a recent case involving Ozempic shows that pharmaceutical companies with popular drugs might face increased competition, without the ability to obtain legal remedies against their competitors.

As the culmination of an SEC investigation into Under Armour Inc.’s “pull forward” practice leads to charges, Under Armour agrees to cease and desist and settles for $9 million.

Following an investigation dating back to 2015, the SEC claimed Under Armour misled investors by not disclosing the reason for